Tetra Therapeutics

Tetra Therapeutics is a biotechnology company founded in 2010 with a mission to develop medicines for various neurological disorders including Alzheimer's Disease, Fragile X syndrome, Traumatic Brain Injury, major depression, and schizophrenia. The company's drugs focus on a new mechanism targeting PDE4B and PDE4D, aiming to address memory loss and cognitive impairment by improving how the brain processes and stores information. Tetra's most promising drug, BPN-14770 for Alzheimer's Disease, is developed in partnership with the NIH Blueprint Therapeutics program. Moreover, the PDE4B platform also targets neuroinflammation, progressive multiple sclerosis (MS), and chronic traumatic encephalopathy (CTE). In November 2016, Tetra Therapeutics secured a $5.00M Series A investment from Dolby Ventures, Grand Angels, Apjohn Ventures, and the Alzheimer's Drug Discovery Foundation. Overall, Tetra Therapeutics is at the forefront of developing innovative treatments for various neurological conditions with a unique approach to targeting brain function and neuroinflammation.